Diagnosis and treatment of GH deficiency in Prader–Willi syndrome

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Prader–Willi syndrome (PWS) results from under-expression of the paternally-derived chromosomal region 15q11-13. Growth failure is a recognized feature of PWS, and both quantitative and qualitative defects of the GH/IGF-I axis revealing GH deficiency (GHD) have been demonstrated in most children with PWS. In PWS adults, criteria for GHD are biochemically fulfilled in 8–38% of the studied cohorts. Published data support benefits of early institution of GH therapy (GHT) in PWS children, with positive effects on statural growth, body composition, metabolic homeostasis, and neurocognitive function. Like in pediatric PWS, GHT also yields beneficial effects on lean and body fat, exercise capacity, and quality of life of PWS adults. Although GHT has been generally administered safely in PWS children and adults, careful surveillance of risks is mandatory during prolonged GH replacement for all PWS individuals.

Original languageEnglish
Pages (from-to)785-794
Number of pages10
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
Volume30
Issue number6
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Therapeutics
Growth
Body Composition
Insulin-Like Growth Factor I
Adipose Tissue
Homeostasis
Quality of Life
Exercise
Pediatrics

Keywords

  • GH deficiency
  • GH therapy
  • Prader–Willi syndrome
  • short stature

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{2e17d55ddcdc43a3a4995b6154a5e9c5,
title = "Diagnosis and treatment of GH deficiency in Prader–Willi syndrome",
abstract = "Prader–Willi syndrome (PWS) results from under-expression of the paternally-derived chromosomal region 15q11-13. Growth failure is a recognized feature of PWS, and both quantitative and qualitative defects of the GH/IGF-I axis revealing GH deficiency (GHD) have been demonstrated in most children with PWS. In PWS adults, criteria for GHD are biochemically fulfilled in 8–38{\%} of the studied cohorts. Published data support benefits of early institution of GH therapy (GHT) in PWS children, with positive effects on statural growth, body composition, metabolic homeostasis, and neurocognitive function. Like in pediatric PWS, GHT also yields beneficial effects on lean and body fat, exercise capacity, and quality of life of PWS adults. Although GHT has been generally administered safely in PWS children and adults, careful surveillance of risks is mandatory during prolonged GH replacement for all PWS individuals.",
keywords = "GH deficiency, GH therapy, Prader–Willi syndrome, short stature",
author = "Graziano Grugni and Paolo Marzullo",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.beem.2016.11.003",
language = "English",
volume = "30",
pages = "785--794",
journal = "Best Practice and Research in Clinical Endocrinology and Metabolism",
issn = "1521-690X",
publisher = "Bailliere Tindall Ltd",
number = "6",

}

TY - JOUR

T1 - Diagnosis and treatment of GH deficiency in Prader–Willi syndrome

AU - Grugni, Graziano

AU - Marzullo, Paolo

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Prader–Willi syndrome (PWS) results from under-expression of the paternally-derived chromosomal region 15q11-13. Growth failure is a recognized feature of PWS, and both quantitative and qualitative defects of the GH/IGF-I axis revealing GH deficiency (GHD) have been demonstrated in most children with PWS. In PWS adults, criteria for GHD are biochemically fulfilled in 8–38% of the studied cohorts. Published data support benefits of early institution of GH therapy (GHT) in PWS children, with positive effects on statural growth, body composition, metabolic homeostasis, and neurocognitive function. Like in pediatric PWS, GHT also yields beneficial effects on lean and body fat, exercise capacity, and quality of life of PWS adults. Although GHT has been generally administered safely in PWS children and adults, careful surveillance of risks is mandatory during prolonged GH replacement for all PWS individuals.

AB - Prader–Willi syndrome (PWS) results from under-expression of the paternally-derived chromosomal region 15q11-13. Growth failure is a recognized feature of PWS, and both quantitative and qualitative defects of the GH/IGF-I axis revealing GH deficiency (GHD) have been demonstrated in most children with PWS. In PWS adults, criteria for GHD are biochemically fulfilled in 8–38% of the studied cohorts. Published data support benefits of early institution of GH therapy (GHT) in PWS children, with positive effects on statural growth, body composition, metabolic homeostasis, and neurocognitive function. Like in pediatric PWS, GHT also yields beneficial effects on lean and body fat, exercise capacity, and quality of life of PWS adults. Although GHT has been generally administered safely in PWS children and adults, careful surveillance of risks is mandatory during prolonged GH replacement for all PWS individuals.

KW - GH deficiency

KW - GH therapy

KW - Prader–Willi syndrome

KW - short stature

UR - http://www.scopus.com/inward/record.url?scp=85003533220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85003533220&partnerID=8YFLogxK

U2 - 10.1016/j.beem.2016.11.003

DO - 10.1016/j.beem.2016.11.003

M3 - Review article

AN - SCOPUS:85003533220

VL - 30

SP - 785

EP - 794

JO - Best Practice and Research in Clinical Endocrinology and Metabolism

JF - Best Practice and Research in Clinical Endocrinology and Metabolism

SN - 1521-690X

IS - 6

ER -